| Literature DB >> 35649614 |
Sandra Walsh1,2, G Lorimer Moseley2, Richard John Gray3,4, Marianne Gillam2,4, Kate M Gunn2,5, Trevor Barker2, Kham Tran2,6, Tesfahun Eshetie5, Martin Jones7,4.
Abstract
BACKGROUND: Behavioural activation (BA) is an effective treatment for depression; however, it is unclear if it can be used to manage pain.Entities:
Keywords: pain management; rehabilitation medicine; social medicine
Mesh:
Year: 2022 PMID: 35649614 PMCID: PMC9161098 DOI: 10.1136/bmjopen-2021-056404
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 3.006
Figure 1PRISMA flow chart. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Characteristics of included studies
| Study | Study design/ methodology | Aim/research question/s | Population | n = | Pain and pain measures | Setting | Intervention | Outcome/ |
| Brooks | Mixed-methods - pre- and post-intervention and semi-structured interview | To examine acceptability, feasibility, and preliminary effectiveness of BA-PR | 50 years+comorbid chronic pain and mental health conditions | 8 | Comorbid chronic pain. | Community-based ageing centre and Community-based mental health site. | BA-PR 6 weeks, 2 hours, group-based, weekly, older peer and clinician co-facilitated pain rehab intervention | Non-significant reductions in pain intensity. Improvements in active and passive pain coping strategies. |
| Hooker | Single-arm, mixed methods—preintervention and postintervention and interview at follow-up | To evaluate feasibility and acceptability of BA in urban family medicine clinic. | 18+living with chronic pain | 30 | Chronic pain. PROMIS | Primary care clinic (urban family medicine clinic). | 10 min or less values-based BA. Two parts: (a) values card sort (b) values-based BA (goal setting). | Statistically significant reduction in mean pain interference (p=0.001) baseline (26.3 SD 4.1) to follow-up (24.8 SD 5.0) |
| Hopko | Uncontrolled preliminary clinical trial—pre, post, 3 months follow-up. | To assess effectiveness of BATD among depressed cancer patients in primary care. | 18+, cancer, diagnosis MDD moderate severity | 6 | Chronic pain. | Primary care. | BATD: 9×1 hour including psychoeducation, treatment rationale, activity and goal selection, and BA. | Significant improvement SF-36 BP means pre- (40.0 SD 16.0) to post-treatment (52.3 SD 29.4) moderate effect size (d 0.5). 3 months follow-up (68.3 SD 28.6) treatment gains maintained (nonsignificant) |
| Hopko | RCT | To conduct a randomised trial using BATD, comparing it to PST for depressed breast cancer patients. | 18+years women diagnosed with breast cancer and moderate -severe MDD | 80 | Bodily pain. | University medical care setting. | BATD and PST. BATD 8 sessions x 1 hour. | SF-36 BP - BATD showed significantly more post-treatment improvement than PST. BATD showed continued post-treatment improvement on 7/14 outcomes, compared with PST (2/14). |
| Hopko | Pre–post study Measures pretreatment and post-treatment, 3 months follow-up. | To examine frequency and significance of sudden gains experienced by depressed cancer patients undergoing brief BA | 18+years, cancer patients with moderate to severe MDD. | n=37 pre-treatment phase, n=26 completed BA protocol. | Chronic pain. | University medical centre. | 9-sessions. - Contemporary BA (CB intervention with BA core component) and ‘pure’ BA. | Individuals with sudden gain had less severe depression, less somatic anxiety, greater physical functioning, less bodily pain. |
| Kim | Case study | To detail the assessment and use of BA to treat a patient with low back and bilateral foot pain. | Veteran 30-year-old, single, African American female,3-year history low back pain, 10 years bilateral foot pain | 1 | Low back pain and bilateral foot pain. | Home | nine sessions. BA proposed to Veteran as intervention to help re-establish purpose-driven activities. | NRS avg pain level pre- 7, range 5–8 previous week; post-treatment 8, range 7 to 8. Four-week follow-up avg pain 7, range 5 to 7 previous week. PCS pre-=32 post-treatment=7. PDI pre-=42/70; post-treatment=32/70. |
| Moitra | Case study | To reduce pain-related interference in physical and psychosocial functioning | PLWH | 1 | Comorbid chronic pain depression. | Community – therapist office and telephone-based. | 7-sessions, 4 core strategies to improve domains of health and well-being. | No outcomes reported |
| Pimentel | Uncontrolled study, pre, mid and post measures | To examine sequential relation between symptom catastrophising and PTSD severity | Work-disabled adults with PTSD referred to an occupational rehabilitation service. | 73 (n=39 women, n=34 men) | Chronic pain. | Occupational rehabilitation service. | PGAP—10-week standardised risk targeted BA to facilitate return to work. | Significant reductions in scores on MPQ-SF, t(72) = 4.9, p<0.001, d=0.59. |
| Plagge | Uncontrolled trial, premeasures and postmeasures | To explore preliminary clinical effectiveness and feasibility of BA to treat comorbid chronic pain and PTSD | Iraqi veterans self-reported pain (3+months), significant PTSD symptoms. | n=58 (full sample) 30 (completers) | Chronic pain. Chronic Pain Grade (Pain severity and Pain interference), PCS | Veterans Affairs Medical Centre. | Adapted BA for Treatment of PTSD manual. 8×75–90 mins individual sessions | Pain severity: pre- 6.8 (1.4); mid- 6.1 (2.0); post-5.8 (2.2). Pain interference: pre- 6.9 (2.1); mid- 5.1 (2.4); post-4.9 (2.5); Pain catastrophising pre- 32.9 (13.0); post-intervention 23.9 (10.5). |
| Quijano | Uncontrolled study, pre and post measures. | To evaluate BA for depression delivered to high-risk, diverse older adults by case managers. | All new and existing clients 60+years in community, receive services at community-based service. Age: range not reported (all clients M=75.9 SD 9.5; eligible M=72.5 SD 9.4) | n=49 measured on QoL (pain); 42 people participated in BA—unknown if they were the same people | Chronic pain. | Two non-profit community-based agencies and one county social service agency. | Contemporary BA identifying behavioural goals important to individual patients. | Pain reduced to no-mild pain 16.3% (baseline) 44.9% (6 months). % participants reporting change in pain significant (p=0.003). |
| Sullivan | Uncontrolled study, pre, mid and post measures—crossed-lagged panel de-sign | To examine the role of perceived injustice as a determinant of symptom severity in individuals with MDD. | Work-disabled adults with MDD at occupational rehabilitation service. Age range not reported (males M=45.8 SD 9.8 females M=45.2 SD 9.8) | 253 | Chronic pain. | Occupational rehabilitation service. | PGAP—10 week standardised risk targeted BA to facilitate return to work. | Significant reductions in pain pretreatment 4.5(SD 2.5) mid-treatment 4.1 (SD 2.4) post-treatment 3.5 (SD 2.3) (p<0.001 Cohen’s d 0.42) |
| Turner and Jakupcak 2010 | Single case study | To describe BA for PTSD and depressive symptoms in veteran with physical injuries | 22 years male soldier PTSD—multiple severe fractures, pain left leg | 1 | Weight bearing pain. | Veterans Administration inpatient rehab unit (initial admission) and two primary care practices. | Weekly treatment over 4 months; based on BA protocol by Jacobson | Recovered from physical injuries and surgeries, weight bearing pain reduced from 8 to 0, improved ambulation. |
| Uebelacker | RCT. Assessments at baseline, 1 2 3 months (endpoint), 4 months (1 month follow-up). | To assess feasibility and acceptability of BA for pain and depressive symptoms in PLWH. | 18+PLWH; 6 months chronic pain; pain interference BPI-I | 23 | Chronic pain. Average pain in past week - NRS (10-point scale - 10 reflecting greater pain). | Two primary care practices | HIV-PASS -modified manualised BA for primary care. | Effect size for avg pain in HE direction. BPI medium effect favouring HIV-PASS. Means decreased at 1 2 3 4 months for BPI and avg pain. |
| Wagner | Small, randomised effectiveness trial | To examine the impact of BA on PTSD (and range of factors that contribute to avoidance including pain) | Adults recently injured with PTSD 1-month post-injury, recruited from surgical ward. Age: range not reported (BA M=28.0 SD 15.4 TAU M=39.0 SD 16.2) | Total n=8 | Chronic pain (some injury related). | Community - Harborview Medical Centre Seattle | BA over 6 sessions 60–90 min each. | PCS-12 pre-treatment BA 34.2 (5.0) TAU 30.6 (8.7); post-treatment BA 35.7 (8.3) TAU 25.4 (8.1). BA reported higher physical function. |
| Yamada | Uncontrolled study, pre and post measures | To examine role of fatigue as determinant of work-disability in individuals with WRMDs | Individual with WRMDs | 117 (n=64 women, n=53 men) | Chronic pain. | Occupational rehabilitation service | PGAP—10-week standardised risk targeted BA to facilitate return to work. | PDI reduced pre (34.9, SD 8.7) to post assessment (27.5, SD 11.7) p value<0.001. NRS reduced pre (6.4, SD 1.8) to post assessment (5.2, SD 2.6) p value<0.001 |
BA-PR, behavioural activation for pain rehabilitation; BATD, behavioural activation treatment for depression; BPI-I, Brief Pain Inventory-Interference scale; CB, cognitive behavioural; MDD, major depressive disorder; MPQ-SF, McGill Pain Questionnaire-Short-Form; NRS, Numerical Rating Scale; PCS, Physical Component Score; PCS, Pain Catastrophising Scale; PDI, Pain Disability Index; PLWH, person/s living with HIV/AIDS; PROMIS, Pain Interference-Short Form scale; PST, problem solving therapy; PTSD, post-traumatic street disorder; RCT, randomised controlled trial; SF, Short Form; SF-36 BP, Medical Outcomes Study Short Form, Bodily Pain component; TAU, treatment as usual; WRMD, work-related musculoskeletal disorders.
Overview of how BA was delivered
| Study | No of sessions | Duration of sessions | Frequency of sessions | Duration of treatment |
| Brooks | 6 | 2 hours | Weekly | 6 weeks |
| Hooker | 3 (including initial visit and follow-up) | 10 min | Once | 3–5 weeks |
| Hopko | 9 | 1 hour | Weekly | 9 weeks |
| Hopko | 9 | 1 hour | Weekly | 9 weeks |
| Hopko | 8 | 1 hour | Weekly | 8 weeks |
| Kim | 10 | Not reported | Not reported | Not reported |
| Moitra | 7 | Not reported | Not reported | Not reported |
| Pimentel | 10 | Not reported | Weekly | 10 weeks |
| Plagge | 8 | 75–90 min | Not reported | Mean no of days between initial in-person contact and intervention completion 110 days, median of 106, range 24–224 |
| Quijano | 10 | Not reported | Not reported | 6 months |
| Sullivan | 10 | Not reported | Weekly | 10 weeks |
| Turner and Jakupcak | 16 | Not reported | Weekly | 4 months (tapering up to 12 months) |
| Uebelacker | 7 | 30–50 min | 2 weeks on average | 3 months |
| Wagner | 4–6 | 60–90 min | Weekly (not always consecutive) | 9.8 weeks avg |
| Yamada | 10 | Not reported | Weekly | 10 weeks |
BA, behavioural activation.
Overview of effect of BA on pain
| Study | Pain measure | Baseline mean (SD) | Mid mean (SD) | Post mean (SD) | Follow-up mean (SD) | P value | D | T |
| Brooks | 0–10 NRS | 7.00 (1.60) | n/a | 6.67 (1.02) | n/a | 0.594 | n/a | 0.558 |
| Hooker | PROMIS | 26.3 (4.1) | n/a | 24.8 (5.0) | n/a | 0.001 | − 0.72 | |
| Hopko | SF36 (Bodily Pain) | 40.0 (16.0) | n/a | 52.3 (29.4) | 68.3 (28.6) | <0.05 | 0.5 | |
| Hopko | SF36 (Bodily Pain) | 44.5 (21.4) (sudden gains) | n/a | n/a | n/a | n/a | n/a | |
| Hopko | SF36 | 46.4 (26.6) | n/a | 55.5 (22.7) | 65.0 (15.3) | <0.05 | 0.33 | |
| Kim | 0–10 NRS | 7 (range 5–8) | n/a | 8 (range 7–8) | n/a | n/a | n/a | |
| PCS | 32, 80th percentile | n/a | 7, 17th percentile | n/a | n/a | n/a | ||
| PDI-recreation | 42/70 | n/a | 32/70 | n/a | n/a | n/a | ||
| Moitra | Pain-related interference | Descriptive | n/a | Descriptive | n/a | n/a | n/a | |
| Pimentel | MPQ-SF | 13.7 (8.0) | 11.5 (7.9) | 9.0 (7.9) | n/a | <0.001 | 0.59 | |
| Plagge | Pain severity (NRS) | 6.8 (1.4) | 6.1 (2.0) | 5.8 (2.2) | n/a | 0.050 | 0.47 | |
| Pain interference (NRS) | 6.9 (2.1) | 5.1 (2.4) | 4.9 (2.5) | n/a | <0.001 | 0.88 | ||
| PCS | 32.9 (13.0) | n/a | 23.9 (10.5) | n/a | <0.001 | 0.79 | ||
| Quijano | SF36 | 16.3% (no pain or mild pain at 6 months) | n/a | 44.9% (no pain or mild pain at 6 months) | n/a | 0.003 | n/r | |
| Sullivan | 11-point NRS | 4.6 (2.5) | 4.1 (2.4) | 3.5 (2.3) | n/a | <0.001 | 0.42 | |
| Turner and Jakupcak | Weight bearing pain (NRS) | 8 | n/a | 5 | 0 | n/a | n/a | |
| Uebelacker | NRS (pain in the past week) | 6.9 (1.6) | n/a | 5.8 (1.3) | n/a | 0.332 | 0.67 (-0.30; 1.64) compared with health education control | |
| BPI-I | 7.3 (1.6) | n/a | 5.5 (1.9) | n/a | 0.566 | −0.39 (-1.36; 0.58) | ||
| Wagner | SF-12 - PCS-12 | 34.2 (5.0) | n/a | 35.7 (8.3) | n/a | 0.05 | n/a | 1.89 |
| Yamada | 11-point NRS | 6.4 (1.8) | n/a | 5.2 (2.6) | n/a | <0.001 | 0.59 | |
| PDI | 34.9 (8.7) | n/a | 27.5 (11.7) | n/a | <0.001 | 0.75 |
BA, behavioural activation; BATD, Behavioural Activation Treatment for Depression; BPI-I, Brief Pain Inventory interference scale; MDD, major depressive disorder; MPQ-SF, McGill Pain Questionnaire-Short-Form; n/a, not applicable; NRS, Numerical Rating Scale; PCS, Pain Catastrophising Scale; PCS, Physical Component Score; PDI, Pain Disability Index; PROMIS, Pain Interference-Short Form scale; SF, Short Form.
Critical appraisal tool for included studies
| Type of study | Critical appraisal tool | Study |
| RCTs | Risk of Bias 2 | Hopko |
| Pre–post studies | National Institutes of Health quality assessment tool for before-and-after (pre–post) study with no control group | Brooks |
| Case studies | Checklist for case reports | Kim |
RCTs, randomised controlled trials.
Randomised controlled trials—Risk of Bias Assessment 2
| Study | Randomisation process | Deviations from intended intervention | Missing outcome data | Measurement of outcome | Selection of reported result | Overall |
| Hopko | High | Some concerns | High | Some concerns | Some concerns | High |
| Uebelacker | High | Major concerns | High | Major concerns | High | High |
| Wagner | High | High | Low | Some concerns | Some concerns | High |
Critical appraisal—National Institutes of Health quality assessment tool for before-and-after (pre–post) study with no control group
| Study | Study question | Selection criteria | Representative | Eligible participants enrolled | Sample size confidence | Intervention clearly described | Outcome measures | Assessors blinded | Loss after baseline | Statistical methods | Repeated measures | Individual level | Overall |
| Brooks | Yes | Yes | No | CD | No | Yes | Yes | NR | Yes | Yes | No | n/a | Fair |
| Hooker | Yes | Yes | CD | CD | NR | Yes | Yes | No | Yes | Yes | No | Yes | Fair |
| Hopko | Yes | Yes | CD | Yes | NR | Yes | Yes | No | No | Yes | Yes | Yes | Fair |
| Hopko | Yes | Yes | CD | CD | NR | Yes | Yes | No | No | Yes | Yes | Yes | Fair |
| Pimentel | Yes | Yes | CD | CD | NR | Yes | Yes | No | Yes | Yes | No | Yes | Fair |
| Plagge | Yes | Yes | CD | Yes | NR | Yes | Yes | No | Yes | Yes | No | Yes | Fair |
| Quijano | Yes | Yes | CD | Yes | NR | Yes | Yes | No | No | Yes | No | Yes | Fair |
| Sullivan | Yes | Yes | CD | Yes | NR | Yes | Yes | No | Yes | Yes | No | Yes | Fair |
| Yamada | No | Yes | CD | Yes | R | Yes | Yes | No | Yes | Yes | No | Yes | Fair |
CD, cannot determine; n/a, not applicable; NR, no reported.
Critical appraisal—checklist for case reports
| Study | Demographics | History | Clinical condition | Assessment | Interventions | Post-intervention | Adverse events | Takeaway | Overall |
| Kim | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Good |
| Moitra | No | No | No | No | Yes | No | No | No | Poor |
| Turner and Jakupcak | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Good |